Keros Therapeutics Files 8-K: Exit, Disposal, and Financials
Ticker: KROS · Form: 8-K · Filed: May 29, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | May 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, restructuring, financials
TL;DR
Keros filed an 8-K on May 28th, looks like they're dealing with exit/disposal costs and financial statements.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on May 29, 2025, reporting events as of May 28, 2025. The filing indicates information related to cost associated with exit or disposal activities, other events, and financial statements and exhibits. Specific financial details or the nature of the exit/disposal activities are not elaborated in the provided text.
Why It Matters
This filing signals potential restructuring or strategic shifts within Keros Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing mentions 'Cost Associated with Exit or Disposal Activities,' which can indicate significant operational changes or financial restructuring that carry inherent risks.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- May 28, 2025 (date) — Earliest event reported
- May 29, 2025 (date) — Date of report
- 001-39264 (company) — SEC File Number
- 811173868 (company) — EIN
FAQ
What specific activities are associated with the 'Cost Associated with Exit or Disposal Activities' mentioned in the filing?
The provided text does not specify the nature of the exit or disposal activities, only that costs are associated with them.
What are the key financial statements and exhibits being filed with this 8-K?
The filing indicates that financial statements and exhibits are included, but the specific details of these documents are not provided in the text.
What is the significance of the 'Other Events' item reported in this 8-K?
The filing lists 'Other Events' as an item of information but does not provide any details about what these events entail.
When was Keros Therapeutics, Inc. incorporated, and in which jurisdiction?
Keros Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Keros Therapeutics, Inc.?
The principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 29, 2025 regarding Keros Therapeutics, Inc. (KROS).